Celularity (NASDAQ:CELU) Shares Down 3.7% - Here's Why

Key Points

• Celularity's stock dropped 3.7% to $2.07 during trading, significantly underperforming with a volume decline of 65% compared to its average daily trading volume.
• Several analysts have mixed views on Celularity, with Wall Street Zen downgrading their rating from "hold" to "sell," while WBB Securities upgraded it from "hold" to "buy" with a $6.00 target price.
• The company reported a negative earnings per share of ($1.02) and had a negative net margin of 165.22%, indicating ongoing financial challenges despite a recent raise in stake by institutional investors.

Celularity, Inc. (NASDAQ:CELU - Get Free Report) dropped 3.7% during trading on Tuesday . The company traded as low as $2.03 and last traded at $2.07. Approximately 73,872 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 212,923 shares. The stock had previously closed at $2.15.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CELU shares. Wall Street Zen downgraded shares of Celularity from a "hold" rating to a "sell" rating in a research note on Friday, September 5th. WBB Securities raised Celularity from a "hold" rating to a "buy" rating and set a $6.00 target price for the company in a report on Tuesday, September 9th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $6.00.

Celularity Stock Performance

The company has a debt-to-equity ratio of 4.07, a current ratio of 0.25 and a quick ratio of 0.19. The stock has a market capitalization of $55.25 million, a PE ratio of -0.65 and a beta of 0.81. The stock has a 50 day moving average of $2.96 and a two-hundred day moving average of $2.27.

Celularity (NASDAQ:CELU - Get Free Report) last issued its earnings results on Friday, August 29th. The company reported ($1.02) earnings per share (EPS) for the quarter. The company had revenue of $5.74 million during the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%.

Institutional Trading of Celularity

Several large investors have recently bought and sold shares of CELU. Bank of America Corp DE raised its stake in shares of Celularity by 1,538.1% during the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock worth $73,000 after buying an additional 35,023 shares during the last quarter. XTX Topco Ltd lifted its stake in Celularity by 106.4% in the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock valued at $42,000 after buying an additional 11,057 shares in the last quarter. Valmark Advisers Inc. acquired a new stake in Celularity during the 2nd quarter valued at $98,000. Acadian Asset Management LLC purchased a new position in Celularity during the first quarter worth $34,000. Finally, Two Sigma Investments LP acquired a new position in shares of Celularity in the fourth quarter worth $93,000. Institutional investors and hedge funds own 19.02% of the company's stock.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.